Helicobacter pylori eradication in West Asia: A review

Table 2 Randomized controlled trials for Helicobacter pylori eradication in Iran

Ref.	Type of patients	Type of triple therapy regimens	Number of patients in each study arm	Eradication rate (%)
				Per-protocol	Intention-to-treat
Mirzaee et al[21], 2012	NA	PAC-7, PAC-7 with yoghourt, PAC-7 with probiotic	34-34-34	61.3-73.1-64.5	NA
Sarkeshikian et al[24], 2013	PUD + NUD	OAC-10, OAAz-10	76-89	83-75	NA
Keshavarz et al[25], 2007	NUD	OAC-14, OAC[half dose]-14	80-80	89-88	83.7-85
Malekzadeh et al[19], 2003	Cancer Screening	OAC-7, OFT-4, OFT-7	45-41-42	42.1-20.6-29.4	35.5-17.1-23.8
Ahmad et al[82], 2013	PUD + NUD	OAF-7, OAF-7 with probiotic	33-33	70-90	70-90
Roghani et al[83], 2003	DU	OAF-14, OAF-14 [half dose]	63-61	88.9-67.9	76.2-62.3
Seyedmajidi et al[26], 2013	PUD	OAC-14, OABM-14, OCPen-14	110-110-110	90.8-56-87	80.9-50.9-79
Ghadir et al[81], 2011	PUD	OAF-14, OABF-14	43-43	61.1-85.3	51.2-67.4
Taghavi et al[27], 2009	NUD	OAC-14, O.Co.Dox.-14, OABF-14	53-67-69	70-63-56	66-61-49
Sotudehmanesh et al[52], 2001	DU	RBTM-14, RBTM-21, OBCT-14	74-73-76	73-71-88	68-68-80
Malekzadeh et al[49], 2000	DU	RABM-14, RABF-14	53-53	56-82	55-75
Khatibian et al[48], 2007	PUD	OABM-14, OABF-14, OABF (first week) M (second week)	107-104,103	83.1-95.2,95.3	74.5-87,86.6
Shidfar et al[51], 2012	NS	OABM-14, OABM-14 + Lycopen	27-27	68-77.8	62.9-77.8
Mousavi et al[50], 2006	PUD, NUD	OABM-14, OAzBM-7	65-64	75.7-78.1	70.4-74.1
Agah et al[47], 2009	NUD	OABM-14, OABAz[first 7 d]-14	30-30	69-68	NA
Mirbagheri et al[20], 2006	NUD	OAC-7, OABM-10, O.Am.BM-10	120-120-120	91.1-85.5-92.8	84.1-86.6-80.8
Shavakhi et al[84], 2013	PUD	OABC-14, OABC-14 with probiotic	90-90	84.4-82.1	81.1-76.6
Fakheri et al[79], 2001	DU	OABC-14, OABF-14	55-63	90-90	85-84
Daghaghzadeh et al[78], 2007	PUD, NUD	OABF-7, OABF-14	78-78	84.8-82.6	71.8-73.1
Fakheri et al[80], 2004	DU	OAF-14, OABF(low dose F)-14, OABF-14	50-50-50	54-72-92	54-72-92
Aminian et al[22], 2010	Dyspepsia	OA-MC-10, OABM-14, OAC-10, OCCip[first 7 d]-14	107-107-107	81.1-85.7-90.7-70	80.4-84-90.7-65
Fakheri et al[69], 2012	DU	PA-CT-10, PA-BF[7]-14	148-148	89.1-88.7	83.7-80.4
Sardarian et al[68], 2013	DU	PA-CT-10, PA-CT-14 (HYBRID)	210-210	79.9-92.9	76.7-89.5
Riahizadeh et al[23], 2010	PUD, NUD	OAB-MF-10, OAC-10, OAB-CF-10	107-106-106	91.3-90.4-88.7	78.5-81.1-82

O: Omeprazole; R: Rabeprazole; A: Amoxicillin; C: Clarithromycine; Az: Azithrmycine; Cip: Ciprofluxacin; Pen: Penbactam; Of: Ofloxaciline; Co: Co-amoxicalv; Dox: Doxycylcine; F: Furazolidone; T: Tetracycline; M: Metronidazole; B: Bismuth subcitrate; NA: not available; PUD: Peptic ulcer disease; NUD: Non-ulcer dyspepsia.